How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of proactive chemistry, manufacturing, and controls strategies.
Louis Cicchini, PhD, and Michael Day, PhD
Advertisement
Articles by Louis Cicchini, PhD, and Michael Day, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
3
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
4
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
5